quarta-feira, 7 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 2, 2026

The Walt Disney Company Reports First Quarter Earnings for Fiscal 2026

View original at finance.yahoo.com
The Walt Disney Company Reports First Quarter Earnings for Fiscal 2026 BURBANK, Calif., February 02, 2026--(BUSINESS WIRE)--The Walt Disney Company (NYSE:DIS) today reported earnings for its first quarter ended December 27, 2025…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Entertainment segment operating income will be comparable to Q2 FY2025 in Q2 FY2026

    80% confidence
  • Entertainment segment operating income will show double-digit growth for full year FY2026, weighted to second half

    80% confidence
  • SVOD operating margin will reach 10% for full year FY2026

    80% confidence
  • Sports segment operating income will decline by $100M in Q2 FY2026

    80% confidence
  • Adjusted EPS will show double-digit growth for full year FY2026

    80% confidence
  • CEO is incredibly proud of all that Disney has accomplished over the past three years

    80% confidence
  • Cash from operations will be $19B for full year FY2026

    80% confidence
  • Disney delivered strong box office performance in calendar year 2025 with billion-dollar hits like Zootopia 2 and Avatar: Fire and Ash, franchises that generate value across many of Disney's businesses

    80% confidence
  • Disney is on track with $7B stock repurchase program for FY2026

    80% confidence
  • Sports segment operating income will show low-single digit growth for full year FY2026

    80% confidence
  • Experiences segment operating income will show high-single digit growth for full year FY2026, weighted to second half

    80% confidence
  • Disney is pleased with the start to fiscal year 2026 and achievements reflect tremendous progress made

    80% confidence
  • SVOD operating income will be approximately $500M in Q2 FY2026, representing $200M increase over Q2 FY2025

    80% confidence

Data points we hold from this source

The Walt Disney Company · corporate expenses304000000 USD
The Walt Disney Company · current borrowings10800000000 USD
The Walt Disney Company · depreciation1000000000 USD
The Walt Disney Company · diluted eps1.40 USD
The Walt Disney Company · domestic parks capex2300000000 USD
The Walt Disney Company · entertainment capex293000000 USD
The Walt Disney Company · long term debt35800000000 USD
The Walt Disney Company · treasury stock9500000000 USD
The Walt Disney Company · interest expense net275000000 USD
The Walt Disney Company · income before taxes3700000000 USD
The Walt Disney Company · international parks capex357000000 USD
The Walt Disney Company · total equity114000000000 USD
The Walt Disney Company · receivables15100000000 USD
The Walt Disney Company · capital expenditures3000000000 USD
The Walt Disney Company · total assets202100000000 USD
The Walt Disney Company · cash from operations735000000 USD
The Walt Disney Company · tax rate32.7 percent
The Walt Disney Company · segment operating income5100000000 USD
The Walt Disney Company · adjusted eps1.76 USD
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
The Walt Disney Company Reports First Quarter Earnings for Fiscal 2026 — Source | Via News | pt.VIA.NEWS